Status:
COMPLETED
The Effect of Bevacizumab on Corneal Neovascularization
Lead Sponsor:
Instituto de Olhos de Goiania
Conditions:
Corneal Neovascularization
Eligibility:
All Genders
18-65 years
Phase:
PHASE4
Brief Summary
Eight patients with corneal neovascularization were treated with subconjunctival injection of 1.25 mg bevacizumab and had a follow-up of at least 2 months. All patients had persistent corneal neovascu...
Detailed Description
To evaluate the effect of repeated subconjunctival bevacizumab (Avastin®, Roche, Rio de Janeiro, Brazil) on inflammatory corneal neovascularization. Eight patients with corneal neovascularization wer...
Eligibility Criteria
Inclusion
- Corneal Neovascularization
- Stable lesion
Exclusion
- Diabetes
- Autoimmune diseases
Key Trial Info
Start Date :
January 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2008
Estimated Enrollment :
8 Patients enrolled
Trial Details
Trial ID
NCT00797303
Start Date
January 1 2006
End Date
November 1 2008
Last Update
December 2 2011
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.